Clinical trialObservationalRecruiting
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital
- Outcome
- Ongoing
- Phase
- Observational
- Status
- Recruiting
- Study type
- Observational
- Start
- 1 July 2024
- Expected end
- 1 March 2027
- Enrollment
- 37 participants
- Sites
- 1
- Primary outcomes
- Objective response rate, ORR
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 26 June 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.